Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.85 |
| ▸ | EGFR | P00533 | 19/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.71 |
| ▸ | KDR | P35968 | 2/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.71 |
| ▸ | TEK | Q02763 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213640 | 0.89 | EGFR (0.85) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL26637 | 0.88 | FBP1 (0.84) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL3238953 | 0.88 | FBP1 (0.84) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL30912752 | 0.88 | FBP1 (0.84) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL22336753 | 0.88 | FBP1 (0.92) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL18660007 | 0.87 | FBP1 (0.82) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL12788058 | 0.86 | EGFR (0.72) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL24685941 | 0.85 | FBP1 (0.69) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL18655499 | 0.85 | EGFR (0.85) | FBP1EGFRERBB2KDRAURKA | |
| SCHEMBL17520369 | 0.84 | EGFR (0.85) | FBP1EGFRERBB2KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FBP1 4684/4885EGFR 2/4885ERBB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.